Current guidelines from the American Urological Association strongly recommend shared decision making for men aged 55 to 69 years considering prostate-specific antigen (PSA) screening, weighing the benefits of reducing the rate of metastatic prostate cancer and prevention of prostate cancer death against the known potential harms associated with screening and treatment (8). This evidence concerns the gene KLK3 and prostate carcinoma.